Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

BACKGROUND: This phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms’ tumor protein 1 (WT1) administered alone or following lymphodepleting chemotherapy, in the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyi, Chrisann, Doubrovina, Ekaterina, Zhou, Qin, Kravetz, Sara, Iasonos, Alexia, Aghajanian, Carol, Sabbatini, Paul, Spriggs, David, O'Reilly, Richard J, O’Cearbhaill, Roisin E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388302/
https://www.ncbi.nlm.nih.gov/pubmed/34433633
http://dx.doi.org/10.1136/jitc-2021-002752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388302/
https://www.ncbi.nlm.nih.gov/pubmed/34433633
http://dx.doi.org/10.1136/jitc-2021-002752

Ejemplares similares